Research Analysts Offer Predictions for GPCR Q4 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR) – Equities researchers at Leerink Partnrs issued their Q4 2025 earnings estimates for shares of Structure Therapeutics in a report issued on Monday, March 3rd. Leerink Partnrs analyst D. Risinger forecasts that the company will earn $2.58 per share for the quarter. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ FY2026 earnings at ($1.41) EPS, FY2027 earnings at ($1.46) EPS and FY2028 earnings at ($1.53) EPS.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01.

GPCR has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. William Blair began coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Stifel Nicolaus initiated coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target for the company. Finally, JMP Securities reiterated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Stock Performance

GPCR stock opened at $22.49 on Wednesday. Structure Therapeutics has a fifty-two week low of $19.61 and a fifty-two week high of $62.74. The company’s 50 day moving average price is $26.34 and its 200 day moving average price is $33.37. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -30.39 and a beta of -2.75.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its position in Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after acquiring an additional 1,420 shares during the period. Assetmark Inc. increased its holdings in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after purchasing an additional 719 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Structure Therapeutics during the third quarter worth $1,337,000. Dearborn Partners LLC purchased a new position in Structure Therapeutics in the 3rd quarter valued at $202,000. Finally, Natixis Advisors LLC increased its stake in Structure Therapeutics by 40.4% in the 3rd quarter. Natixis Advisors LLC now owns 26,675 shares of the company’s stock valued at $1,171,000 after buying an additional 7,670 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.